Aktis Oncology (AKTS) vs Mentari Therapeutics (MTRI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Aktis Oncology is the larger company by market cap ($901.1 million vs $856.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AKTS | MTRI |
|---|---|---|
| Share price | $16.15 | $14.70 |
| Market cap | $901.14M | $856.94M |
| 1-day change | -1.52% | -3.57% |
| EPS (TTM) | $-1.80 | — |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $34.19 | $23.30 |
| 52-week low | $13.96 | $5.75 |
| Distance from 52-week high | -52.76% | -36.91% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +122.17% | — |
| Average volume | 408.46K | 19.42K |
| Shares outstanding | 53.93M | 58.30M |
| Employees | 79 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Aktis Oncology
AKTS stock →Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 79 employees
About Mentari Therapeutics
MTRI stock →Mentari Therapeutics, Inc., a biotechnology company, develops and provides therapies for migraine prevention. The company's products include MT-001, an anti-PACAP monoclonal antibody designed for convenient subcutaneous dosing; MT-002, an anti-CGRP; and anti-PACAP bispecific antibody designed to inhibit these complementary pathways.
Health Care · Biotechnology: Pharmaceutical Preparations
AKTS vs MTRI FAQ
Which is bigger, Aktis Oncology or Mentari Therapeutics?
Aktis Oncology (AKTS) is larger, with a market capitalization of $901.14M compared with $856.94M for Mentari Therapeutics (MTRI).
Are Aktis Oncology and Mentari Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.